Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine (original) (raw)
Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study
Dick Veltman
Schizophrenia Research, 2017
View PDFchevron_right
Craving in Patients with Schizophrenia and Cannabis Use Disorders
Thomas Schnell
The Canadian Journal of Psychiatry, 2013
View PDFchevron_right
The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study
Dick Veltman
Journal of Psychopharmacology, 2014
View PDFchevron_right
Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone
Suzannah Zimmet
Schizophrenia Research, 2003
View PDFchevron_right
Pharmacotherapy of Co-Occurring Schizophrenia and Substance Use Disorders
Mary Brunette
Current Addiction Reports, 2014
View PDFchevron_right
Psychopharmacological comparison of schizophrenia spectrum disorder with and without cannabis dependency
Zoltan Makkos, Lilla Fejes
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2011
View PDFchevron_right
Substance abuse and schizophrenia: Pharmacotherapeutic intervention
Mary Brunette
Journal of Substance Abuse Treatment, 2008
View PDFchevron_right
Biological aspects of cannabis consumption in schizophrenia
dan madalina
Archives of Biological Sciences, 2014
View PDFchevron_right
Occupancy of dopamine D2 receptors by the atypical antipsychotic drugs risperidone and olanzapine: theoretical implications
Anissa Abi-Dargham
Psychopharmacology, 2004
View PDFchevron_right
Quetiapine in patients with comorbid schizophrenia-spectrum and substance use disorders: an open-label trial
Emmanuel Stip
Current Medical Research and Opinion, 2006
View PDFchevron_right
Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia
Lieuwe de Haan
Psychopharmacology, 2005
View PDFchevron_right
Dopaminergic Mechanisms in Idiopathic and Drug-induced Psychoses
Bruce J Kinon
Schizophrenia Bulletin, 1990
View PDFchevron_right
Striatal dopamine D2 receptor binding of risperidone in schizophrenic patients as assessed by 123I-iodobenzamide SPECT: a comparative study with olanzapine
Thomas Frodl
Journal of Psychopharmacology, 2002
View PDFchevron_right
Clozapine, quetiapine and olanzapine among addicted schizophrenic patients: towards testable hypotheses
Emmanuel Stip
International Clinical Psychopharmacology, 2003
View PDFchevron_right
Neurobiology of Comorbid Substance Use Disorders in Mental Illness: A Closer Look at the Underlying Commonalities between Cannabis and Schizophrenia
Rishab Gupta
Current Addiction Reports, 2014
View PDFchevron_right
The neuropsychology of cannabis and other substance use in schizophrenia: review of the literature and critical evaluation of methodological issues
Michael Perdices
Australian and New Zealand Journal of Psychiatry, 2007
View PDFchevron_right
The endocannabinoid system in schizophrenia
Paul Morrison
View PDFchevron_right
Medial prefrontal cortical D2 and striatolimbic D4 dopamine receptors : Common targets for typical and atypical antipsychotic drugs
Ross Baldessarini
Progress in Neuro Psychopharmacology Biological Psychiatry, 1998
View PDFchevron_right
Dopamine Hypothesis of Schizophrenia Revisited
Naveed Iqbal
Psychiatric Annals, 1993
View PDFchevron_right
Half a century of antipsychotics and still a central role for dopamine D2 receptors
David Mamo
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2003
View PDFchevron_right
Striatal dopamine-2 receptor occupancy in psychotic patients treated with risperidone
Johannes Tauscher
Psychiatry Research: Neuroimaging, 1996
View PDFchevron_right
Substance use disorders and schizophrenia: A question of shared glutamatergic mechanisms
Joseph T Coyle
Neurotoxicity Research, 2006
View PDFchevron_right
Dopamine D2 receptor occupancy with risperidone or olanzapine during maintenance treatment of schizophrenia: A cross-sectional study
Bruce Pollock
Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2012
View PDFchevron_right
Differential dopamine release by psychosis-generating and non-psychosis-generating addictive substances in the nucleus accumbens and dorsomedial striatum
Louise Adermark
Translational Psychiatry, 2021
View PDFchevron_right
Cannabinoids for the Treatment of Schizophrenia? A Balanced Neurochemical Framework for Both Adverse and Therapeutic Effects of Cannabis Use
Michael Perdices
Schizophrenia Research and Treatment, 2011
View PDFchevron_right
A prospective comparison of two models of cannabis use and psychotic relapse in early psychosis
Sharon Dawe, David Kavanagh
View PDFchevron_right
Cannabis and Schizophrenia
Juan Negrete
Marihuana and Medicine, 1999
View PDFchevron_right
Equivalent Occupancy of Dopamine D1 and D2 Receptors With Clozapine: Differentiation From Other Atypical Antipsychotics
Johannes Tauscher
American Journal of Psychiatry, 2004
View PDFchevron_right
Variable individual sensitivity to cannabis in patients with schizophrenia
Alain Dervaux
The International Journal of Neuropsychopharmacology, 2010
View PDFchevron_right
Antipsychotics Management in Addictive Disorders
Benjamin Rolland
Current Psychopharmacology, 2014
View PDFchevron_right